The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
MedPage Today on MSN
Amputation Risk in Diabetes Drops With GLP-1 Drugs, Study Suggests
Association driven by fewer major amputations ...
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...
According to CNIO, among the various kinds of cancer, pancreatic cancer remains one of the deadliest and is a widely known ...
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...
Jerry Shapiro, MD, discusses strategies for treating patients with scarring and nonscarring alopecia.
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now available in ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —— Savolitinib ...
Data from up to 42 months of treatment reinforce lucerastat's potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is finali ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results